Enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: Central retinal enrichment supplementation trials - Report 1

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 7, 2016, Pages 3429-3439

  Nolan, John M ^a   Power, Rebecca ^a   Stringham, Jim ^b   Dennison, Jessica ^a   Stack, Jim ^a   Kelly, David ^a   Moran, Rachel ^a   Akuffo, Kwadwo O ^a   Corcoran, Laura ^a   Beatty, Stephen ^a  

^a South East Technological University   (Ireland)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Contrast sensitivity; Glare disability; Lutein; Macular pigment; Meso zeaxanthin; Randomized clinical trial; Visual acuity; Visual function

Indexed keywords

CAROTENOID; MESO ZEAXANTHIN; PLACEBO; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN; MESO-ZEAXANTHIN; VISUAL PIGMENT;

ADULT; ARTICLE; AUTOFLUORESCENCE; BEST CORRECTED VISUAL ACUITY; BODY MASS; CONTRAST SENSITIVITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EYE FUNDUS; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE AGED; NORMAL HUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; CONVALESCENCE; DIETARY SUPPLEMENT; DRUG EFFECT; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA LUTEA; VISUAL ACUITY;

ADULT; ANALYSIS OF VARIANCE; CONTRAST SENSITIVITY; DIETARY SUPPLEMENTS; FEMALE; HUMANS; LUTEIN; MACULA LUTEA; MACULAR PIGMENT; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; STRESS, PSYCHOLOGICAL; VISUAL ACUITY; ZEAXANTHINS;

EID: 84994571112     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-19520     Document Type: Article

References (64)

1. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Invest Ophthalmol Vis Sci. 1993;34:2033-2040.
2. Bone RA, Landrum JT, Friedes LM, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997;64:211-218.
3. Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys. 2001;385:28-40.
4. Bernstein PS, Li B, Vachali PP, et al. Lutein, zeaxanthin, and meso-zeaxanthin: the basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res. 2016;50:34-66.
5. Chew E. The AREDS2 Study Group. Lutein þ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005-2015.
6. Chew EY, Clemons TE, SanGiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2013;132:142-149.
7. Akuffo KO, Nolan JM, Howard AN, et al. Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration. Eye (Lond). 2015;29:902-912.
8. Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci. 1997;38:1802-1811.
9. Li B, Ahmed F, Bernstein PS. Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch Biochem Biophys. 2010;504:56-60.
10. Snodderly DM, Brown PK, Delori FC, Auran JD. The macular pigment. I. absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci. 1984;25:660-673.
11. Beatty S, Koh HH, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
12. Loughman J, Davison PA, Nolan JM, Akkali MC, Beatty S. Macular pigment and its contribution to visual performance and experience. J Optom. 2010;3:74-90.
13. Schultze M. Ueber den gelben Fleck der Retina. Seinen Einfluss auf normales Sehen und auf Farbenblindheit. Bonn:Cohen & Sohn; 1866.
14. Walls GL, Judd HD. The intra-ocular colour-filters of vertebrates. Br J Ophthalmol. 1933;17:705-725.
15. Nussbaum JJ, Pruett RC, Delori FC. Historic perspectives. Macular yellow pigment. The first 200 years. Retina. 1981;1:296-310.
16. Werner JS, Donnelly SK, Kliegl R. Aging and human macular pigment density. Appended with translations from the work of Max Schultze and Ewald Hering. Vision Res. 1987;27:275-268.
17. Wooten BR, Hammond BR. Macular pigment: influences on visual acuity and visibility. Prog Retin Eye Res. 2002;21:225-240.
18. McLellan JS, Marcos S, Prieto PM, Burns SA. Imperfect optics may be the eye’s defence against chromatic blur. Nature. 2002;417:174-176.
19. Williams DR, Coletta NJ. Cone spacing and the visual resolution limit. J Opt Soc Am A. 1987;4:1514-1523.
20. Stringham JM, Hammond BR. Macular pigment and visual performance under glare conditions. Optom Vis Sci. 2008;85:82-88.
21. Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry NR, Berendschot TT. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Invest Ophthalmol Vis Sci. 2013;54:1781-1788.
22. Hammond BR Jr, Wooten BR, Smollon B. Assessment of the validity of in vivo methods of measuring human macular pigment optical density. Optom Vis Sci. 2005;82:387-404.
23. Bartlett HE, Eperjesi F. Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. Eur J Clin Nutr. 2007; 61:1121-1127.
24. Rodriguez-Carmona M, Kvansakul J, Harlow JA, Kopcke W, Schalch W, Barbur JL. The effects of supplementation with lutein and/or zeaxanthin on human macular pigment density and colour vision. Ophthalmic Physiol Opt. 2006;26:137-147.
25. Yao Y, Qiu QH, Wu XW, Cai ZY, Xu S, Liang XQ. Lutein supplementation improves visual performance in Chinese drivers: 1-year randomized, double-blind, placebo-controlled study. Nutrition. 2013;29:958-964.
26. Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci. 1988;29:843-849.
27. Akuffo KO, Beatty S, Stack J, et al. Central Retinal Enrichment Supplementation Trials (CREST): design and methodology of the CREST randomized controlled trials. Ophthalmic Epidemiol. 2014;21:111-123.
28. Thurnham DI, Nolan JM, Howard AN, Beatty S. Macular response to supplementation with differing xanthophyll formulations in subjects with and without age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2015;253:1231-1243.
29. Nolan JM, Akkali MC, Loughman J, Howard AN, Beatty S. Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment. Exp Eye Res. 2012;101:9-15.
30. Loughman J, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S. The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci. 2012;53:7871-7880.
31. Sabour-Pickett S, Beatty S, Connolly E, et al. Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration. Retina. 2014;34:1757-1766.
32. Friedman LM, Furberg CD, Demets DL. Fundamentals of Clinical Trials. 4th ed. New York: Springer; 2010.
33. Nolan JM, Loskutova E, Howard A, et al. The impact of supplemental macular carotenoids in Alzheimer’s disease: a randomized clinical trial. J Alzheimers Dis. 2015;44:1157-1169.
34. Hohberger B, Laemmer R, Adler W, Juenemann AG, Horn FK. Measuring contrast sensitivity in normal subjects with OPTEC 6500: influence of age and glare. Graefes Arch Clin Exp Ophthalmol. 2007;245:1805-1814.
35. Nolan JM, Loughman J, Akkali MC, et al. The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. Vision Res. 2011;51:459-469.
36. Dennison JL, Stack J, Beatty S, Nolan JM. Concordance of macular pigment measurements obtained using customized heterochromatic flicker photometry, dual-wavelength autofluorescence, and single-wavelength reflectance. Exp Eye Res. 2013;116:190-198.
37. Nolan JM, Loskutova E, Howard AN, et al. Macular pigment, visual function, and macular disease among subjects with Alzheimer’s disease: an exploratory study. J Alzheimers Dis. 2014;42:1191-1202.
38. Hartridge H. Visual acuity and the resolving power of the eye. J Physiol. 1922;57:52-67.
39. Marmor MF, Martin LJ. 100 years of the visual cycle. Surv Ophthalmol. 1978;22:279-285.
40. Land EH. Recent advances in retinex theory and some implications for cortical computations: color vision and the natural image. Proc Natl Acad Sci U S A. 1983;80:5163-5169.
41. Richman J, Lorenzana LL, Lankaranian D, et al. Importance of visual acuity and contrast sensitivity in patients with glaucoma. Arch Ophthalmol. 2010;128:1576-1582.
42. Trieschmann M, Beatty S, Nolan JM, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007;84:718-728.
43. Nolan JM, Meagher K, Kashani S, Beatty S. What is mesozeaxanthin, and where does it come from? Eye (Lond). 2013; 27:899-905.
44. Gorusupudi AF, Shyam RF, Li BF, et al. Developmentally regulated production of meso-zeaxanthin in chicken retinal pigment epithelium/choroid and retina. Invest Ophthalmol Vis Sci. 2016;57:1853-1861.
45. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. Human photoreceptor topography. J Comp Neurol. 1990;292:497-523.
46. Kuffler SW. Discharge patterns and functional organization of mammalian retina. J Neurophysiol. 1953;16:37-68.
47. Wandell BA. The retinal representation. In: Foundations of Vision. Chapter 5. Sunderland, MA: Sinauer Associates, Inc.; 1995. Available at: https://foundationsofvision.stanford.edu/ chapter-5-the-retinal-representation.
48. Gouras P. The effects of light-adaptation on rod and cone receptive field organization of monkey ganglion cells. J Physiol. 1967;192:747-760.
49. Campbell FW, Robson JG. Application of Fourier analysis to the visibility of gratings. J Physiol. 1968;197:551-566.
50. Moiseyev G, Nikolaeva O, Chen Y, Farjo K, Takahashi Y, Ma JX. Inhibition of the visual cycle by A2E through direct interaction with RPE65 and implications in Stargardt disease. Proc Natl Acad Sci U S A. 2010;107:17551-17556.
51. Bhosale P, Serban B, Bernstein PS. Retinal carotenoids can attenuate formation of A2E in the retinal pigment epithelium. Arch Biochem Biophys. 2009;483:175-181.
52. Stringham JM, Garcia PV, Smith PA, McLin LN, Foutch BK. Macular pigment and visual performance in glare: benefits for photostress recovery, disability glare, and visual discomfort. Invest Ophthalmol Vis Sci. 2011;52:7406-7415.
53. Stringham JM, Garcia PV, Smith PA, et al. Macular pigment and visual performance in low-light conditions. Invest Ophthalmol Vis Sci. 2015;56:2459-2468.
54. Stringham NT, Stringham JM. Temporal visual mechanisms may mediate compensation for macular pigment. Perception. 2015;44:1400-1415.
55. Vielma A, Delgado L, Elgueta C, Osorio R, Palacios AG, Schmachtenberg O. Nitric oxide amplifies the rat electroretinogram. Exp Eye Res. 2010;91:700-709.
56. Torralba A, Oliva A. Statistics of natural image categories. Network. 2003;14:391-412.
57. Rae S, Latham K, Katsou MF. Meeting the UK driving vision standards with reduced contrast sensitivity. Eye (Lond). 2016; 30:89-94.
58. Marottoli RA, Richardson EDFAU, Stowe MHFAU, et al. Development of a test battery to identify older drivers at risk for self-reported adverse driving events. J Am Geriatr Soc. 1998:46:562-568.
59. Green M. "How long does it take to stop?" Methodological analysis of driver perception-brake times. 2000;2:195-216.
60. Driver and Vehicle Licensing Agency. At a glance guide to the current medical standards of fitness to drive. 2014. Available at: www.dft.gov.uk/dvla/medical/ataglance.aspx.
61. European Parliament. Commission Directive 2009/113/EC of 25 August2009onamendingDirective2006/126/ECoftheEuropean Parliament and of the Council on driving licences. 2009. 24-2-2016. Available at: http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri1/4OJ:L:2009:223:0031:0035:EN:PDF.
62. van den Berg TJ. Importance of pathological intraocular light scatter for visual disability. Doc Ophthalmol. 1986;61:327-333.
63. Abrahamsson M, Sjostrand J. Impairment of contrast sensitivity function (CSF) as a measure of disability glare. Invest Ophthalmol Vis Sci. 1986;27:1131-1136.
64. Directive 2007/59/EC of the European Parliament and of the council of the 23 October 2007 on the certification of train drivers operating locomotives and trains on the railway system in the Community. 2007. Available at: http://eur-lex.europa. eu/legal-content/EN/TXT/?uri1/4CELEX:02007L0059-20140715.